Bingham partner Carl Valenstein and counsel Kelly Grez represented ClearPath Development Company in a strategic partnership with Astellas Pharma Inc. to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership, established to support Astellas’ goal of building a global vaccine franchise, launched its first company, RSV Corporation, in December 2013. Astellas will fund RSV Corporation’s development of a virosome vaccine technology for respiratory syncytial virus (RSV), a respiratory pathogen that can infect patients of all ages and can be especially severe in infants and older adults with chronic pulmonary or cardiovascular disease. Currently there is no vaccine available for RSV, which infects 64 million people worldwide each year and is responsible for 160,000 deaths. ClearPath, a subsidiary of RRD International, works with leading biopharmaceutical companies to expand product pipeline opportunities with complementary development and finance capabilities.